Syndax(SNDX) - 2024 Q3 - Quarterly Results
SNDXSyndax(SNDX)2024-11-06 05:02

Exhibit 99.1 Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update – New revumenib and Niktimvo™clinical data will be highlighted at 66 th ASH Annual Meeting – – mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 – – Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – – Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic t ...